Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Total Non-Current Liabilities: 2019

  • Avidity Biosciences' Total Non-Current Liabilities was N/A to $27.5 million in Q4 2019 from the same period last year, while for Dec 2019 it was $27.5 million, marking a year-over-year change of. This contributed to the annual value of $27.5 million for FY2019, which is N/A change from last year.
  • Latest data reveals that Avidity Biosciences reported Total Non-Current Liabilities of $27.5 million as of Q4 2019.
  • In the past 5 years, Avidity Biosciences' Total Non-Current Liabilities ranged from a high of $27.5 million in Q4 2019 and a low of $27.5 million during Q4 2019.
  • Moreover, its 1-year median value for Total Non-Current Liabilities was $27.5 million (2019), whereas its average is $27.5 million.